Navigation Links
MELA Sciences, Inc., a Leader in the Fight Against Melanoma, Participates in the American Society of Dermatologic Surgery Annual Meeting

IRVINGTON, N.Y., Oct. 2, 2013 /PRNewswire/ -- MELA Sciences, Inc. (NASDAQ: MELA), the medical device company that developed and is commercializing MelaFind®, the first and only FDA-approved optical diagnostic device for melanoma detection used by dermatologists in their fight against melanoma, will participate in the American Society of Dermatologic Surgery (ASDS) Annual Meeting from October 3-6, 2013, at the Hyatt Regency in Chicago, Illinois.

(Logo: )

The four-day event is an educational opportunity for the Society's dermatologists and dermatologic surgeons to stay abreast of innovative devices, news and technology. As part of the meeting, MELA Sciences' Interim Chief Executive Officer, Robert Coradini, and his team will be showcasing the Company's flagship product, MelaFind®, at booth 1000.

Attendees at the meeting will have access to in-depth information about MelaFind®, receive live demonstrations and connect one-on-one with the Company's executives.

Melanoma is currently the deadliest and fastest growing cancer in the U.S., with one American dying from melanoma every hour. Skin cancer has reached epidemic proportions, even though the cause (ultraviolet rays) and prevention (sun protection) is known. Melanoma is almost 100% curable if caught early, but only 24 percent of American adults have had a skin check by a dermatologist, which can lead to missed cases as well as potentially advanced and fatal stages.

"MelaFind® is successfully being implemented in dermatologists' offices in the United States and Germany and we are committed to raising awareness of the disease and helping dermatologists fight this deadly epidemic with MelaFind® as an advanced tool to help in diagnosis," said Robert Coradini, Interim CEO for MELA Sciences. "It is the only FDA approved and CE Marked optical diagnostic device for melanoma detection, which non-invasively and painlessly takes 3-D images of a mole as deep as 2.5mm below the skin's surface with multi-spectral light and analyzes 75 key features with proprietary algorithms to aid dermatologists with useful information in their biopsy decisions of ambiguous moles."

"The results obtained from a MelaFind® exam combined with my expertise in dermatology and knowledge of patient histories helps me to make the best decision for my patients when examining atypical lesions," said Darrell Rigel, MD, Clinical Professor of Dermatology, New York University and recently named Chief Medical Advisor to the Board of Directors of MELA Sciences, Inc. "Using MelaFind®, I can see up to 2.5mm beneath the surface of the skin to obtain information I wouldn't have seen using the naked eye."

MelaFind® has been recognized by the Cleveland Clinic as a Top 10 Medical Innovation for 2013 and was recently featured in The Wall Street Journal. Consumers can learn more about the device or locate a dermatologist with MelaFind® in their area by visiting

About MELA Sciences, Inc.
MELA Sciences, Inc. is a medical device company focused on the commercialization of its flagship product, MelaFind® and its further design and development. MelaFind® is a non-invasive tool that provides additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device supplies information on a lesion's level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind® has been approved by the U.S. Food and Drug Administration for use in the U.S. In addition, MelaFind® has received CE Mark approval and is approved for use in the European Union.

For more information on MELA Sciences, Inc., visit

Safe Harbor:
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes," "assumes," "predicts" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved. Actual results may differ materially from our beliefs or expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the company and the medical device industry in general, as well as more specific risks and uncertainties facing the company such as those set forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission (the "SEC"). Factors that might cause such a difference include whether MelaFind® achieves market acceptance. Given the uncertainties affecting companies in the medical device industry such as the Company, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. The Company urges you to carefully review and consider the disclosures found in its filings with the SEC which are available at and


SOURCE MELA Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
2. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
3. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
4. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
5. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
6. Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference
7. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
8. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
9. Jaipal Reddy, Honble Minister of Science and Technology & Earth Sciences, Inaugurates the International Bioenergy Summit in Delhi
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
Post Your Comments:
(Date:10/8/2015)... N.J. , Oct. 8, 2015  Genetic testing ... may aid the identification of more couples at risk ... a study presented today at the 2015 American Society ... October 10 in Baltimore, Maryland . ... Quest Diagnostics (NYSE: DGX ) are presenting at ...
(Date:10/8/2015)... October 8, 2015 ... --> Goldman Small Cap Research, a ... cap and microcap sectors, announced today that it ... PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly ... and preparing treatments for cancer and diabetes. To ...
(Date:10/8/2015)... -- The ALS Association, in partnership with Prize4Life, is pleased ... communication technology solutions for people living with ALS. ... lateral sclerosis) is a progressive neurodegenerative disease that affects ... cord. Eventually, people with ALS lose the ability to ... total paralysis and death within two to five years ...
(Date:10/8/2015)... ... October 08, 2015 , ... Talon Innovations, a provider of Precision Machined ... announces that it is one of three finalists for the Minnesota Business magazine’s Manufacturing ... September 25 Talon Innovations was recognized as a nominee for this competitive award. ...
Breaking Biology Technology:
... Wisconsin has a chance to attract a major federal laboratory. It ... Health Center was established in Madison, and nearly 100 years ... University of Michigan as the site for the ... the world's knowledge of wildlife diseases and forests - as well ...
... - The origins of Madison's technology industry can be ... isolated when he opened DNASTAR, Inc . that year. , ... - and a few more, the producer of DNA analysis ... era where it was considered bad form - even a social ...
... Valuable business advice and $25,000 in cash prizes will ... hold the 2007 Northeast Wisconsin Business Plan Contest ... business, or existing businesses that are changing direction, in ... $10,000 first place reward, entrepreneurs will receive advice about ...
Cached Biology Technology:
(Date:9/30/2015)... PALM BEACH GARDENS, Fla. , Sept. 30, 2015 ... Circuit earlier this month issued another key ruling in ... Commission,s (ITC,s) determination that Korean fingerprint scanner company Suprema ... the Tariff Act of 1930, a trade provision that ... connection with import trade, by infringing two of Crossmatch,s ...
(Date:9/28/2015)... , Sept. 28, 2015 ... today that its expedited traveler service is ... platform transforms travel, bringing a frictionless experience, ... members. "CLEAR offers our travelers ... customer service," said Jim Smith , ...
(Date:9/28/2015)... SAN JOSE, Calif. , Sept. 28, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that Lenovo ... area touch fingerprint sensor, FS4202, for its latest smartphone, ... enables secure, password-free access to unlock the device and ... consumers. The feature-rich Natural ID FS4202 ...
Breaking Biology News(10 mins):
... FINDINGS: Using a new in vivo screening system, Whitehead ... metabolic pathway that is essential in estrogen receptor (ER)-negative ... codes for this proteinphosphoglycerate dehydrogenase or PHGDHis suppressed in ... protein, the rate of cellular growth declines markedly. ...
... published recently in PLoS One delivers new insight ... rattlesnakes may be engaged in an arms race with opossums, ... long been known to eat venomous snakes, this fact has ... of snake venom. Instead, snake venom is usually seen as ...
... from the John Theurer Cancer Center at Hackensack University ... the recently concluded American Society of Clinical Oncology (ASCO) ... 2011 in Chicago. The studies examined new cancer treatments, ... quality of life issues. "ASCO is a ...
Cached Biology News:
... : Recombinant human HMGN2/HMG-17 Formulation: ... 0.15M NaCl, 0.05% sodium azide ... to 30% Quality Assurance: routinely ... extracts of murine 10T 1/2 ...
... Dr. P Set from different human ... More organs maybe available upon request. ... items from the whole set, and ... price. All Dr. P Set ...
... Steady gravity-fed delivery of buffer and ... perfusion. Rat version. In Vivo Manual ... gravity-fed delivery of buffer and fixative ... to setup, use and clean--Complete system ...
Biology Products: